DongKoo Bio&Pharma Co. Ltd
DongKoo Bio&Pharma. Co., Ltd. researches, develops, manufactures, and sells medicines in South Korea. The company offers prescribed medicines, such as liver disease, skeletal muscle relaxant, endocrine system, brain nervous system, urogenital, antiobestic, digestive system, circulatory organ, allergenic, mental disease, oral dermatology, external preparation of dermatology, antiseptic, antiviral,… Read more
DongKoo Bio&Pharma Co. Ltd (006620) - Total Assets
Latest total assets as of September 2025: ₩269.00 Billion KRW
Based on the latest financial reports, DongKoo Bio&Pharma Co. Ltd (006620) holds total assets worth ₩269.00 Billion KRW as of September 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
DongKoo Bio&Pharma Co. Ltd - Total Assets Trend (2015–2024)
This chart illustrates how DongKoo Bio&Pharma Co. Ltd’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
DongKoo Bio&Pharma Co. Ltd - Asset Composition Analysis
Current Asset Composition (December 2024)
DongKoo Bio&Pharma Co. Ltd's total assets of ₩269.00 Billion consist of 43.9% current assets and 56.1% non-current assets.
| Asset Category | Amount (KRW) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₩25.37 Billion | 10.4% |
| Accounts Receivable | ₩19.91 Billion | 8.2% |
| Inventory | ₩45.96 Billion | 18.8% |
| Property, Plant & Equipment | ₩66.22 Billion | 27.1% |
| Intangible Assets | ₩13.17 Billion | 5.4% |
| Goodwill | ₩0.00 | 0.0% |
Asset Composition Trend (2015–2024)
This chart illustrates how DongKoo Bio&Pharma Co. Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: DongKoo Bio&Pharma Co. Ltd's current assets represent 43.9% of total assets in 2024, an increase from 40.9% in 2015.
- Cash Position: Cash and equivalents constituted 10.4% of total assets in 2024, up from 0.6% in 2015.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 5.0% of total assets, an increase from 2.0% in 2015.
- Asset Diversification: The largest asset category is property, plant & equipment at 27.1% of total assets.
DongKoo Bio&Pharma Co. Ltd Competitors by Total Assets
Key competitors of DongKoo Bio&Pharma Co. Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
AGP Ltd
KAR:AGP
|
Pakistan | PKRs28.27 Billion |
|
Sam Chun Dang Pharm. Co. Ltd
KQ:000250
|
Korea | ₩529.96 Billion |
|
NatureCell Co.Ltd
KQ:007390
|
Korea | ₩71.32 Billion |
|
Sam-A Pharm. Co. Ltd
KQ:009300
|
Korea | ₩246.13 Billion |
|
Kyung Dong Pharmaceutical Co. Ltd
KQ:011040
|
Korea | ₩291.47 Billion |
|
WooGene B&G Co. Ltd
KQ:018620
|
Korea | ₩117.10 Billion |
|
Oscotec Inc
KQ:039200
|
Korea | ₩154.14 Billion |
|
EstechPharma Co. Ltd
KQ:041910
|
Korea | ₩192.01 Billion |
DongKoo Bio&Pharma Co. Ltd - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Strong asset utilization - DongKoo Bio&Pharma Co. Ltd generates 1.02x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Moderate ROA - For every $100 in assets, DongKoo Bio&Pharma Co. Ltd generates $ 0.83 in net profit.
DongKoo Bio&Pharma Co. Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.92 | 0.99 | 1.79 |
| Quick Ratio | 0.46 | 0.59 | 1.17 |
| Cash Ratio | 0.00 | 0.23 | 0.00 |
| Working Capital | ₩-9.01 Billion | ₩ -1.46 Billion | ₩ 31.84 Billion |
DongKoo Bio&Pharma Co. Ltd - Advanced Valuation Insights
This section examines the relationship between DongKoo Bio&Pharma Co. Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.27 |
| Latest Market Cap to Assets Ratio | 0.00 |
| Asset Growth Rate (YoY) | 27.7% |
| Total Assets | ₩244.06 Billion |
| Market Capitalization | $57.77 Million USD |
Valuation Analysis
Below Book Valuation: The market values DongKoo Bio&Pharma Co. Ltd's assets below their book value (0.00 x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: DongKoo Bio&Pharma Co. Ltd's assets grew by 27.7% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for DongKoo Bio&Pharma Co. Ltd (2015–2024)
The table below shows the annual total assets of DongKoo Bio&Pharma Co. Ltd from 2015 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | ₩244.06 Billion | +27.71% |
| 2023-12-31 | ₩191.10 Billion | +11.07% |
| 2022-12-31 | ₩172.06 Billion | +11.16% |
| 2021-12-31 | ₩154.79 Billion | +7.23% |
| 2020-12-31 | ₩144.35 Billion | +8.76% |
| 2019-12-31 | ₩132.73 Billion | +27.28% |
| 2018-12-31 | ₩104.28 Billion | +37.95% |
| 2017-12-31 | ₩75.59 Billion | +15.74% |
| 2016-12-31 | ₩65.31 Billion | +7.47% |
| 2015-12-31 | ₩60.77 Billion | -- |